Conferences

Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Real-world Results for Preventing Infections in CLL and Non-Hodgkin Lymphoma Patients

November 15, 2024

New study shows IVIG replacement lowers infection risk in CLL and NHL patients, highlighting the need for better IgG testing and IgRT guidelines.

Discussing Unmet Clinical Needs in CLL with Silvia Deaglio, MD, PhD

August 27, 2024

Dr. Deaglio outlines two CLL groups that need special attention from researchers to advance treatment options.

EHA 2024: 4 Years on, Ibrutinib + Venetoclax Keeps High-Risk CLL in Remission

July 22, 2024

Dr. Jacobs shared findings about the outcomes of a fixed-duration treatment combination of ibrutinib and venetoclax for patients with high-risk CLL.

ASCO 2024: Reducing Ibrutinib Dose Impacts Time to Next CLL Treatment

July 09, 2024

Dr. Shadman presented data showing that lowering the ibrutinib dose can be safe for patients with CLL who experienced side effects.

What is the ASCO Conference?

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

Navigating Clinical Trials: Breaking Down Barriers for Underrepresented Patients

April 08, 2024

Dr. Rouce illuminates the comprehensive steps taken to overcome various obstacles in clinical trial recruitment among underrepresented populations.

Revolutionizing CAR T-Cell Therapy: A Breakthrough in Patient Care

March 06, 2024

Medical researchers are helping CAR T-cell production become more accessible by using mobile clean rooms and increasing production locations.

ASH 2023: Do CLL Patients Prefer Fixed-Duration or Continuous-Duration Therapy?

February 14, 2024

Researchers conducted a study to find out if CLL patients prefer being treated for a set period of time and then stopping or being treated indefinitely.

ASH 2023: How Effective is Venetoclax After a BTK Inhibitor for CLL?

February 12, 2024

Dr. Ghosh shared how venetoclax is effective as a second or third-line therapy for CLL patients who were previously treated with a covalent BTK inhibitor.